Amgen’s Bispecific Blinatumomab May Be Ready For Leukemia Filing
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Single-arm, Phase II data in relapsed acute lymphoblastic leukemia could suffice, firm says, for what would be the first-ever U.S. approval of an engineered bispecific antibody.